ReviewCommunications biology2026
Prospects of DNA nanotechnology in stroke repair and regeneration.
Review in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke remains a significant global cause of death and long-term disability, with limited effective treatments for repairing and regenerating damaged brain tissue. Conventional therapy primarily focuses on acute care and preventing recurrence, but it falls short in restoring lost neural function. Recent advances in DNA nanotechnology, enabling precise molecular engineering, targeted delivery, and dynamic bio-functional platforms, offer promising avenues to address this gap. DNA nanostructures have been explored for various stroke therapies, including neuroprotective drug delivery, promoting angiogenesis, reducing inflammation, and guiding stem cells, thanks to their programmability, biocompatibility, and structural adaptability. Additionally, DNA nanodevices paired with imaging agents allow real-time monitoring of cerebral repair processes. Recent studies suggest that DNA nanoparticles could enhance neuronal survival, support functional regeneration, and modify the post-stroke environment. Despite these promising developments, significant challenges remain in vivo stability, immunogenicity, large-scale manufacturing, and safety for translation. This review outlines the current applications of DNA nanotechnology in stroke repair and regeneration, offering mechanistic insights into their therapeutic roles and prospects for clinical translation of DNA-based nanotherapeutics in neuroregenerative medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.